S.B. Kaye

507 total citations
13 papers, 410 citations indexed

About

S.B. Kaye is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, S.B. Kaye has authored 13 papers receiving a total of 410 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 4 papers in Surgery. Recurrent topics in S.B. Kaye's work include Ovarian cancer diagnosis and treatment (2 papers), Lung Cancer Research Studies (2 papers) and Gastric Cancer Management and Outcomes (2 papers). S.B. Kaye is often cited by papers focused on Ovarian cancer diagnosis and treatment (2 papers), Lung Cancer Research Studies (2 papers) and Gastric Cancer Management and Outcomes (2 papers). S.B. Kaye collaborates with scholars based in United Kingdom, Netherlands and Belgium. S.B. Kaye's co-authors include J. Wanders, Patrick Schöffski, Steven Kaplan, H. R. Franklin, Thomas Cerny, Ron Epelbaum, M Soukop, N. Pavlidis, Jaco J. Verweij and A. van Oosterom and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and The Journal of Urology.

In The Last Decade

S.B. Kaye

13 papers receiving 393 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S.B. Kaye United Kingdom 6 262 147 129 86 54 13 410
Andrea Wahner Hendrickson United States 8 146 0.6× 64 0.4× 61 0.5× 79 0.9× 32 0.6× 17 293
G. Rangoni Italy 10 111 0.4× 68 0.5× 143 1.1× 45 0.5× 69 1.3× 26 362
Angel Yordanov Bulgaria 9 109 0.4× 70 0.5× 60 0.5× 88 1.0× 92 1.7× 101 411
Claudia Lefeuvre‐Plesse France 11 164 0.6× 59 0.4× 77 0.6× 72 0.8× 35 0.6× 36 290
Joseph Haas United States 10 101 0.4× 94 0.6× 111 0.9× 81 0.9× 82 1.5× 18 448
Janine Lombard Australia 11 204 0.8× 64 0.4× 89 0.7× 88 1.0× 26 0.5× 38 395
Alejandro Gallego Spain 10 158 0.6× 55 0.4× 50 0.4× 42 0.5× 24 0.4× 28 279
Joshua A. Halpern United States 10 62 0.2× 170 1.2× 68 0.5× 74 0.9× 109 2.0× 18 397
Giulia Moggio Italy 7 248 0.9× 67 0.5× 33 0.3× 55 0.6× 19 0.4× 12 439
E. Brand United States 11 60 0.2× 85 0.6× 119 0.9× 45 0.5× 86 1.6× 23 366

Countries citing papers authored by S.B. Kaye

Since Specialization
Citations

This map shows the geographic impact of S.B. Kaye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S.B. Kaye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S.B. Kaye more than expected).

Fields of papers citing papers by S.B. Kaye

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S.B. Kaye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S.B. Kaye. The network helps show where S.B. Kaye may publish in the future.

Co-authorship network of co-authors of S.B. Kaye

This figure shows the co-authorship network connecting the top 25 collaborators of S.B. Kaye. A scholar is included among the top collaborators of S.B. Kaye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S.B. Kaye. S.B. Kaye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Ledermann, JA, Timothy Perren, Andrew Embleton-Thirsk, et al.. (2013). Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. UCL Discovery (University College London). 75 indexed citations
2.
Ratain, Mark J., G. K. Schwartz, Amit M. Oza, et al.. (2011). Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT).. Journal of Clinical Oncology. 29(15_suppl). 3079–3079. 18 indexed citations
3.
Ang, Joo Ern, David Olmos, Víctor Moreno, et al.. (2011). Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit.. Journal of Clinical Oncology. 29(15_suppl). 2555–2555. 2 indexed citations
4.
Yap, Tami, H. Pandha, James Spicer, et al.. (2006). 348 POSTER A phase I study of wild-type reovirus, which selectively replicates in cells expressing activated Ras, administered intravenously to patients with advanced cancer. European Journal of Cancer Supplements. 4(12). 108–108. 2 indexed citations
5.
Collette, Laurence, R. Sylvester, P.H.M. de Mulder, et al.. (1999). Serum Alpha-Fetoprotein Surge After the Initiation of Chemotherapy for Non-Seminomatous Testicular Cancer Has an Adverse Prognostic Significance. The Journal of Urology. 162(3 Part 1). 959–959. 1 indexed citations
6.
O'Neill, V J, T.R. Jeffry Evans, & S.B. Kaye. (1997). An audit of Hickman line complications in patients with solid tumours. European Journal of Cancer. 33. S54–S54. 1 indexed citations
7.
Piccart, Martine, Martin Gore, W. ten Bokkel Huinink, et al.. (1995). Docetaxel: an Active New Drug for Treatment of Advanced Epithelial Ovarian Cancer. JNCI Journal of the National Cancer Institute. 87(9). 676–681. 101 indexed citations
8.
Bissett, D., A.N. Harnett, T. Habeshaw, et al.. (1995). Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support. British Journal of Cancer. 71(6). 1279–1282. 8 indexed citations
9.
Cerny, Thomas, Steven Kaplan, N. Pavlidis, et al.. (1994). Docetaxel (TaxotereTM) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG). British Journal of Cancer. 70(2). 384–387. 145 indexed citations
10.
Verweij, Jaco J., et al.. (1993). Phase II study with topotecan in colorectal cancer. European Journal of Cancer. 29. S92–S92. 3 indexed citations
11.
Sulkes, Aarón, F Cavalli, A. van Oosterom, et al.. (1993). Taxotere is active in advanced gastric carcinoma: Results of a phase II clinical trial. European Journal of Cancer. 29. S101–S101. 3 indexed citations
12.
Soukop, M, et al.. (1991). Randomised controlled study of relaxation training. European Journal of Cancer and Clinical Oncology. 27(2). 170–174. 49 indexed citations
13.
Adams, L. G., et al.. (1988). What Should We Tell Patients with Cancer?. Scottish Medical Journal. 33(3). 260–260. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrea Wahner Hendrickson Breakdown of academic impact, for papers by G. Rangoni Breakdown of academic impact, for papers by Angel Yordanov Breakdown of academic impact, for papers by Claudia Lefeuvre‐Plesse Breakdown of academic impact, for papers by Joseph Haas Breakdown of academic impact, for papers by Janine Lombard Breakdown of academic impact, for papers by Alejandro Gallego Breakdown of academic impact, for papers by Joshua A. Halpern Breakdown of academic impact, for papers by Giulia Moggio Breakdown of academic impact, for papers by E. Brand
Rankless by CCL
2026